Hyderabad: DiabetOmics, a global medical diagnostic company has launched a unique diagnostic test Lumella, which provides an accurate and reliable estimate of Glycosylated Fibronectin (GlyFN), a protein biomarker that is elevated in pregnant women with a high risk for developing Preeclampsia, a press release said.
Lumella is a proprietary test developed by DiabetOmics and uses a simple test strip and a hand-held quantitative reader. The test can be done with a finger prick blood sample and in the physician’s clinic. Test results are available in ten minutes and assessment can be completed within the same visit of the pregnant woman to consult with her obstetrician.
The test being simple and easy to use enables its adoption in any setting – remote, rural or urban. The Lumella test system, has recently received regulatory approval in India, said Dr Srinivas Nagalla, Founder & CEO of DiabetOmics.
Preeclampsia, characterised as a hypertensive disorder, is an undesirable complication in pregnancy and can affect both the mother and the baby. It is a complex disease and affects multiple organs and systems in the pregnant woman.